| |
Software Requirements
Microsoft Internet Explorer 5.01 or higher and Netscape Navigator 4.75 or higher are recommended. |
|
 |
J.Health Sci., 54(4), 508-511, 2008
Development of an Enzyme Linked Immunosorbent Assay for Direct Determination of Anticancer Drug Vitamin K3 in Serum
Seiichi Sakamoto,a Junichi Sakoda,a
Osamu Morinaga,b Putalun Waraporn,c
Ryota Tsuchihashi,d Satoshi Morimoto,a
Junei Kinjo,d and Hiroyuki Tanaka*, a
aDepartment of Medicinal Plants Breeding and Pharmacognosy, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan,
bDepartment of Pharmacognosy, Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki 859-3298, Japan,
cDepartment of Pharmacognosy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand, and
dDepartment of Pharmacognosy, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan
Synthetic vitamin K3 (VK3, 2-methyl-1,4-naphthoquinone, or menadione) has been shown to have anticancer activity in various human cancer cells. We developed an enzyme-linked immunosorbant assay (ELISA) for determination of VK3 in fetal calf serum (FCS) without any pretreatment. The monoclonal antibody against VK3, which was secreted from an established hybridoma cell line (3A3) has been proven to have highly specific binding to VK3 in cross-reactivity analysis. The full measuring range of the assay extends from 0.39 to 50 μg/ml of VK3. Based on validation analysis, this immunological analysis is a precise, accurate, and sensitive method for determination of VK3. This simple immunological method would deserve to be applicable clinically.
|
|
